+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Shionogi and Co ltd - logo

Shionogi develops pharmaceutical products for pain, pediatric conditions, infectious diseases, cardiovascular diseases, diabetes, and women's health. It offers products in the form of injections, chewable and oral tablets, capsules, and oral suspensions. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. The company was founded in 2010 and is based in Florham Park, New Jersey.

Cymbalta (duloxetine) Drug Overview 2019 - Product Thumbnail Image

Cymbalta (duloxetine) Drug Overview 2019

  • Report
  • March 2019
  • 25 Pages
  • Global
Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2027 - Product Thumbnail Image

Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2027

  • Report
  • July 2022
  • 100 Pages
  • Global
From
Pediatric Drugs and Vaccines: Global Strategic Business Report - Product Thumbnail Image

Pediatric Drugs and Vaccines: Global Strategic Business Report

  • Report
  • April 2024
  • 292 Pages
  • Global
From
Neuropathic Pain - Pipeline Insight, 2024 - Product Thumbnail Image

Neuropathic Pain - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030 - Product Thumbnail Image

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030

  • Report
  • September 2021
  • 150 Pages
  • Global
From
Zollinger-Ellison Syndrome Treatment Global Market Report 2024 - Product Thumbnail Image

Zollinger-Ellison Syndrome Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
Narcolepsy Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - Product Thumbnail Image

Narcolepsy Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • Report
  • August 2022
  • 122 Pages
  • Global
From
Opioid-Induced Constipation (OIC) (Other Diseases) - Drugs in Development, 2021 - Product Thumbnail Image

Opioid-Induced Constipation (OIC) (Other Diseases) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Global Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Forecast 2023-2030 - Product Thumbnail Image

Global Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Forecast 2023-2030

  • Report
  • March 2024
  • 180 Pages
  • Global
From
Carbapenem-resistant Enterobacteriaceae Infection - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Carbapenem-resistant Enterobacteriaceae Infection - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
  • Global
From
P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021 - Product Thumbnail Image

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

  • Report
  • November 2021
  • 70 Pages
  • Global
From
Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 1127 Pages
  • Global
From
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 240 Pages
  • Global
From
Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 110 Pages
  • Global
From
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 490 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 307 Pages
  • Global
From
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 340 Pages
  • Global
From
Global Urinary Tract Infection Therapeutics Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Thumbnail Image

Global Urinary Tract Infection Therapeutics Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • October 2023
  • 172 Pages
  • Global
From
Hospital Acquired Pneumonia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape - Product Thumbnail Image

Hospital Acquired Pneumonia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

  • Report
  • September 2022
  • 76 Pages
  • Global
From
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) Drug Overview 2019 - Product Thumbnail Image

SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) Drug Overview 2019

  • Report
  • March 2019
  • 20 Pages
  • Global
Loading Indicator